TABLE 1.
In vitro susceptibility of tested MRSA determined by the microdilution method or PAP and analysis of observed PK parameters
| Drug and isolate | MIC (μg/ml)b | MBC (μg/ml) | Half-life (h) | fCmax (μg/ml)a | fCmin (μg/ml)a | T99.9% (h)a | fAUC/MIC (h−1)a | % fTb,c |
|
|---|---|---|---|---|---|---|---|---|---|
| >MIC | >2× MIC | ||||||||
| Ceftaroline | 2.1 ± 0.2 | 17.4 ± 0.7 | 1.3 ± 0.3 | ||||||
| R1629 | 0.125 (0.75) | 0.25 | 12 | 100 (100)/100 (67) | 100 (75)/100 (50) | ||||
| R3804 | 0.25 (0.5) | 0.5 | 26.8 | 100 (100)/100 (67) | 100 (94)/83 (62.5) | ||||
| R4039 | 0.5 (1) | 1 | 6.5 | 100 (94)/83 (62.5) | 100 (69)/62.5 (46) | ||||
| R494 | 0.5 (1.2) | 0.5 | 28.3-35 | 100 (85)/83 (57) | 94 (62.5)/62.5 (42) | ||||
| R5200 | 1 (1) | 1 | 6.8 | 94/62.5 | 69/46 | ||||
| Mu3 | 2 (2) | 2 | 5.05-44 | 69/46 | 47/31 | ||||
| Vancomycin | 6.8 ± 1.6 | 18.0 ± 0.2 | 5.2 ± 1.2 | ||||||
| R1629 | 1 (6) | 2 | 57.9 | ||||||
| R3804 | 0.5 | 1 | 231.8 | ||||||
| R4039 | 1 | 1 | 115.9 | ||||||
| R494 | 0.5 | 1 | 231.8 | ||||||
| R5200 | 0.5 | 0.5 | 231.8 | ||||||
| Mu3 | 2 (6) | 2 | 57.9 | ||||||
a
fCmax, free peak concentration of drug in serum; fCmin, free trough concentration of drug in serum; fAUC, free area under the concentration-time curve; T99.9%, time to achieve bactericidal activity with the q12h regimen.
b
Parentheses indicate values computed with the minimal concentration required to inhibit growth of the subpopulation determined by PAP at an initial inoculum of 107 CFU/ml.
c
%fT > MIC, percentage of time the q8h/q12h dosing regimen is above the MIC.